Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

Zhou, Xing; Jiang, Xiao; Liu, Luzhou; Wang, Xiaoxiong; Li, Chuan; Yao, Yutang; Kou, Ying; Shen, Jiaqi; Shen, Taipeng; Zeng, Li; Yang, Shixing; Zhou, Shengyan; Hong, Lan; Luo, Zhigang; Wu, Xiaoai; Chen, Shirong; Cheng, Zhigang

doi:10.1016/j.tranon.2021.101292

Cited by 9 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xing Zhoe et al, while evaluating BCR in patients following RP, found a high detection rate for patients after radical prostatectomy. In their study, 79% of patients showed at least one pathological finding on 18 F-PSMA-1007 PET/CT [8]. Treglia G et al performed a systematic review and meta-analysis for the detection rate of 18 F-labeled PSMA PET/CT in BCR of PCa and found a pooled diagnostic rate of 81% for 18 F-labeled PSMA PET/CT [9].…”

Section: Discussionmentioning

confidence: 97%

Lessons from a 3-Year Review of PSMA PET-CT in a Tertiary Setting: Can We Fine Tune Referral Criteria by Identifying Factors Predicting Positivity and Negativity?

Pant,

Vinjamuri,

Zanial

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Aim of the study: To draw inferences from a retrospective evaluation of PSMA PET CT scans performed for the evaluation of biochemical recurrence. Material and Methods: A retrospective analysis of 295 PSMA PET CT scans spanning 3 years between 2020 and 2022 was undertaken. Results: Of 295 PET CT scans, 179 were positive, 66 were negative and 50 had indeterminate findings. In the positive group, 67 had radical prostatectomy and PSMA avid lesions were seen most commonly in pelvic lymph nodes. The remaining 112 positive scans were in the non-radical prostatectomy group; 25 had recurrence only in the prostate, 17 had recurrence involving the prostate bed; 28 had no recurrence in the prostate gland, while 42 had recurrence in the prostate as well as in extra-prostatic sites. Overall, in the non-prostatectomy group, 75% of the population was harboring a PSMA avid lesion in the prostate gland while in the remaining 25% of the population, recurrence did not involve the prostate gland. The majority of indeterminate findings were seen in small pelvic or retroperitoneal lymph nodes or skeletal regions (ribs/others) and in nine patients indeterminate focus was seen in the prostate bed only. Follow-up PSMA PET CT was helpful in prior indeterminate findings and unexplained PSA rise. Conclusion: A higher recurrence in the prostate bed while evaluating biochemical recurrence prompts the following: question: should prostatectomy be offered more proactively? Follow-up PSMA PET CT is helpful for indeterminate findings; a PSA rise of 0.7 ng/mL in 6 months can result in positive PSMA PET CT while negative scans can be seen up to a 2 ng/mL PSA rise in 6 months.

show abstract

Section: Discussionmentioning

confidence: 97%

Lessons from a 3-Year Review of PSMA PET-CT in a Tertiary Setting: Can We Fine Tune Referral Criteria by Identifying Factors Predicting Positivity and Negativity?

Pant,

Vinjamuri,

Zanial

et al. 2023

Diagnostics

View full text Add to dashboard Cite

show abstract

“…Most metastases shown by 18 F-PSMA-1007 and 18 F-FDG PET/CT have typical imaging ndings. Existing studies have shown a high correlation between PSMA-positive lesions and pathologically con rmed metastases [37]. We recruited three senior nuclear medicine physicians to read independently to avoid misjudgment.…”

Section: Discussionmentioning

confidence: 99%

18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

Liu

Jiang

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose To explore the value of 18F-PSMA-1007 and 18F-FDG PET/CT in prostate cancer （PCa） patients, this study compared the performance of the two tracers to detect PCa and then analyzed the correlation between the metabolic parameters and serum PSA value. Finally, we evaluated the application of both tracers in the auxiliary staging of PCa patients. Methods Thirty patients diagnosed with PCa who underwent both 18F-PSMA-1007 and 18F-FDG PET/CT were enrolled. The detection rate, number, location of lesions, and metabolic parameters SUVs (SUVmax, SUVmean), PSMA-TV, MTV, TL-PSMA, TLG, and tumor-to-background ratio (TBR) were recorded and compared. The correlation between metabolic parameters and serum PSA was analyzed. Finally, the differences and consistency of both tracers for the same patient’s NM stage and clinical stage were compared. Results Patient analysis showed that 18F-PSMA-1007 PET/CT had a similar ability to identify the primary tumor and local recurrence (p=1.000) as 18F-FDG PET/CT but identified more patients with metastases (p=0.016), especially bone metastases (p=0.004). Lesion analysis showed that 18F-PSMA-1007 PET/CT identified more primary lesions, local recurrences, and metastases. It also had higher diagnostic efficacy for lymph nodes and bone metastases (both p<0.05). For lesions with positive uptake, the median SUVs and TBR of 18F-PSMA-1007 PET/CT were significantly higher than 18F-FDG PET/CT (all p<0.05). The median PSMA-TV was higher than the median MTV. Still, the difference was not statistically significant (p>0.05), while the median TL-PSMA was significantly higher than the median TLG (p<0.05). Volume-based metabolic parameters PSMA-TV, TL-PSMA, MTV, and TLG, were significantly and positively correlated with PSA (all p<0.05). In contrast, SUVs and TBR for the primary tumor or local recurrence were not associated with PSA. 18F-PSMA-1007 PET/CT identified more M1 patients and higher clinical stage, and it had higher diagnostic efficacy than 18F-FDG PET/CT (p<0.05). Conclusions 18F-PSMA-1007 PET/CT was a valuable imaging modality for PCa. It had better diagnostic efficacy, lesions detection, and a higher median value for metabolic parameters than 18F-FDG PET/CT. Volume-based metabolic parameters reflecting the total tumor burden were positively correlated with serum PSA levels. 18F-PSMA-1007 PET/CT had a higher clinical application value than 18F-FDG PET/CT for PCa patients.

show abstract

“…The two most commonly used radiolabels for PSMA are gallium-68 [ 68 Ga] or fluoride-18 [ 18 F] [108,109]. A recent systematic review by Evangelista et al found limited headto-head evidence between the two radiolabels but noted a number of factors to take into account.…”

Section: Detection Of Recurrent Diseasementioning

confidence: 99%

A Review of Modern Imaging Landscape for Prostate Cancer: A Comprehensive Clinical Guide

Gravestock

Somani

Tokas

et al. 2023

JCM

View full text Add to dashboard Cite

The development of prostate cancer imaging is rapidly evolving, with many changes to the way patients are diagnosed, staged, and monitored for recurrence following treatment. New developments, including the potential role of imaging in screening and the combined diagnostic and therapeutic applications in the field of theranostics, are underway. In this paper, we aim to outline the current landscape in prostate cancer imaging and look to the future at the potential modalities and applications to come.

show abstract

Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

Cited by 9 publications

References 25 publications

Lessons from a 3-Year Review of PSMA PET-CT in a Tertiary Setting: Can We Fine Tune Referral Criteria by Identifying Factors Predicting Positivity and Negativity?

Lessons from a 3-Year Review of PSMA PET-CT in a Tertiary Setting: Can We Fine Tune Referral Criteria by Identifying Factors Predicting Positivity and Negativity?

18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

A Review of Modern Imaging Landscape for Prostate Cancer: A Comprehensive Clinical Guide

Contact Info

Product

Resources

About